Welcome to our dedicated page for Silexion Therapeutics news (Ticker: SLXN), a resource for investors and traders seeking the latest updates and insights on Silexion Therapeutics stock.
Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biotechnology innovator advancing RNA interference therapies targeting KRAS-driven cancers, with a focus on pancreatic cancer treatment. This page serves as the definitive source for verified corporate developments, research breakthroughs, and strategic updates.
Investors and researchers will find timely updates on clinical trial progress, including developments around LODER™ and next-gen candidate SIL-204. Our aggregation includes regulatory milestones, partnership announcements with industry leaders like Evonik, and preclinical insights from advanced tumor models.
The curated news collection covers essential categories: clinical study results, intellectual property updates, executive leadership changes, and financial disclosures. Each update is vetted for relevance to SLXN's core mission of developing precision RNAi therapies for treatment-resistant cancers.
Bookmark this page for streamlined access to Silexion's evolving story in oncology innovation. Check regularly for authoritative reporting on therapeutic advancements and scientific collaborations shaping the future of KRAS mutation targeting.
Silexion Therapeutics (NASDAQ:SLXN) has announced breakthrough preclinical data for its pan-KRAS inhibitor SIL204, demonstrating exceptional efficacy across multiple cancer types. The drug achieved 83.5% to 99.7% inhibition in eleven human cell lines across 5 different organ cancer sites.
Key highlights include the first evidence of gastric cancer activity, with 89.2% inhibition in the SNU-601 cell line, and remarkable efficacy in lung cancer cells showing up to 99.7% inhibition. The drug demonstrated activity against eight KRAS mutations (G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D) at nanomolar concentrations.
Silexion plans to advance SIL204 to Phase 2/3 clinical trials in H1 2026, with regulatory submissions scheduled for Q4 2025 in Israel and Q1 2026 in the EU.
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company developing RNAi therapies for KRAS-driven cancers, has regained compliance with Nasdaq's listing requirements. The company has met both the minimum bid price requirement of $1.00 per share and the minimum shareholders' equity requirement of $2.5 million.
The company is preparing for Phase 2/3 clinical trials of its SIL204 therapy, scheduled for the first half of 2026. Recent preclinical data showed promising results with up to 97% inhibition rates across multiple KRAS-driven cancer types. Silexion has also established a strategic CRO collaboration to advance its clinical development strategy.
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech focused on RNA interference therapies for KRAS-driven cancers, has announced the pricing of a $6.0 million public offering. The offering includes 1,500,000 ordinary shares (or equivalents) with accompanying series A and B warrants at $4.00 per share.
The offering includes series A warrants with a 5-year term and series B warrants with a 12-month term, both with a $4.00 exercise price. H.C. Wainwright & Co. is serving as the exclusive placement agent. The proceeds will support pre-clinical studies and general corporate purposes, with closing expected around September 12, 2025.
Silexion Therapeutics (NASDAQ:SLXN) announced positive preclinical data for its pancreatic cancer drug SIL204. The study demonstrated that subcutaneously administered SIL204 successfully reached major pancreatic cancer metastatic sites and showed anti-tumor activity.
Key findings include successful drug distribution to liver, peritoneum, and lung following a single subcutaneous injection at 5mg/mouse, with statistically significant reductions (p<0.01) in tumor burden observed in the peritoneum, lung, and intestine. The results validate the systemic component of Silexion's dual-route administration strategy.
The company remains on track to initiate Phase 2/3 clinical trials in H1 2026, with regulatory submissions planned for Q4 2025 and Q1 2026.
Silexion Therapeutics (NASDAQ:SLXN) has selected AMS Advanced Medical Services GmbH as its Contract Research Organization (CRO) to support upcoming Phase 2/3 clinical trials for SIL204, their RNA interference therapy targeting KRAS-driven cancers.
The partnership follows impressive preclinical results showing up to 97% inhibition in pancreatic cancer cells, ~90% inhibition in colorectal cancer cells, and significant activity in lung cancer cell lines. SIL204 has demonstrated effectiveness against multiple KRAS mutations including G12D, G12V, G12R, Q61H, and G13D.
Regulatory submissions are planned for Q4 2025 (Israel) and Q1 2026 (EU), with Phase 2/3 trials expected to commence in H1 2026. The trials will evaluate SIL204's dual-route administration approach in locally advanced pancreatic cancer patients.
Silexion Therapeutics (NASDAQ:SLXN), a clinical-stage biotech company focused on RNA interference therapies for KRAS-driven cancers, will present at the 27th Annual H.C. Wainwright Global Investment Conference. The presentation is scheduled for September 10, 2025, at 2:00 PM ET at the Lotte New York Palace Hotel.
The company has uploaded an updated corporate presentation to their website's investor section. Management will be available for one-on-one meetings with investors during the conference, which can be arranged through H.C. Wainwright representatives.
Silexion Therapeutics (NASDAQ: SLXN) reported Q2 2025 financial results and business updates, highlighting significant progress in its SIL204 preclinical program for KRAS-driven cancers. The company demonstrated strong efficacy data across multiple cancer types, including 94% inhibition in pancreatic cancer, 90% in colorectal cancer, and significant inhibition in lung cancer cells with KRAS G12D mutations.
Key developments include a strategic partnership with Catalent for formulation development, plans to initiate Phase 2/3 clinical trials in H1 2026, and maintaining Nasdaq listing following a 1-for-15 reverse split. Financial results show cash position of $3.5 million as of June 30, 2025, with Q2 net loss of $2.5 million, up from $1.5 million in Q2 2024.
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company focused on RNAi therapies for KRAS-driven cancers, has announced warrant exercise agreements totaling $1.8 million in gross proceeds. The agreement involves the immediate exercise of 152,106 outstanding warrants at $11.57 per share.
As part of the transaction, the company will issue new unregistered warrants to purchase up to 304,212 ordinary shares at an exercise price of $11.32 per share. These new warrants will have a 24-month term and will become exercisable following shareholder approval of increased authorized shares. H.C. Wainwright & Co. serves as the exclusive placement agent for this offering.
Silexion Therapeutics (NASDAQ: SLXN) has announced breakthrough preclinical data for its RNA interference therapy SIL204, demonstrating exceptional cancer cell growth inhibition rates. The study showed up to 97% inhibition in pancreatic cancer cells and 90% in colorectal cancer cells, including first-time evidence against the KRAS Q61H mutation.
Key findings revealed dose-dependent inhibition of up to 94% in pancreatic cancer cells with KRAS G12D mutations, 97% inhibition in pancreatic cancer cells with KRAS Q61H mutations, and nearly 90% inhibition in colorectal cancer cells with KRAS G12D mutations. The company is preparing for a Phase 2/3 clinical trial in Q2 2026 to investigate SIL204 for KRAS-driven solid tumor cancers.
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company developing RNAi therapies for KRAS-driven cancers, has announced a 1-for-15 reverse share split effective after market close on July 28, 2025. Trading on a split-adjusted basis will begin on July 29, 2025.
The reverse split will automatically combine every fifteen ordinary shares into one share, with the par value increasing from $0.0009 to $0.0135 per share. The move aims to maintain Nasdaq listing compliance and follows recent preclinical breakthroughs with SIL-204. Shareholders holding shares in book-entry form or through brokers will have their shares automatically adjusted.
FAQ
What is the current stock price of Silexion Therapeutics (SLXN)?
What is the market cap of Silexion Therapeutics (SLXN)?
